A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

June 30, 2009

Conditions
Fibrocystic Disease of Breast
Interventions
DRUG

danazol

danazol applied topically once per day for 4 treatment cycles

DRUG

Placebo

placebo topically applied once daily for 4 treatment cycles

Trial Locations (30)

14609

Rochester Clinical Research, Inc., Rochester

20036

James A Simon, M.D., PC, Washington D.C.

23233

Virginia Women's Center, Richmond

30075

Atlanta North Gynecology, PC, Roswell

32607

Southeastern Integrated Medical, LLC, Gainsville

33409

Palm Beach Research Center, West Palm Beach

33437

Visions Clinical Research, Boynton Beach

37403

Southeastern Clinical Research, Chattanooga

38305

Jackson Clinic, Jackson

40504

Kentucky Medical Research Center, Lexington

43213

Columbus Center for Women's Health Research, Columbus

46250

Physician's Research Group, Indianapolis

60612

Center for Women's Research, Chicago

61820

Women's Health Practice, Champaign

78229

Clinical Trials of Texas, Inc., San Antonio

Seven Oaks Women's Center, San Antonio

80220

Horizons Clinical Research Center, LLC, Denver

84107

Salt Lake Research, Salt Lake City

85015

Women's Health Research, Phoenix

85712

Advanced Clinical Therapeutics, LLC, Tucson

89106

Impact Clinical Trials, Las Vegas

90211

Impact Clinical Trials, Beverly Hills

92123

Women's Health Care at Frost Street, San Diego

98105

Women's Clinical Research Center, Seattle

02481-2106

MedVadis Research Corporation, Wellesley Hills

08648

Delaware Valley OB/GYN and Infertility Group, PC, Lawrenceville

08057

Phoenix OB-GYN Associates, Moorestown

08901

UMDNJ Robert Wood Johnson Medica School Women's Health Institute, New Brunswick

10022-1009

Analgesic Development, Ltd., New York

19102-1192

Drexel University College of Medicine, Philadelphia

All Listed Sponsors
lead

FemmePharma Global Healthcare, Inc.

INDUSTRY

NCT00744276 - A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease | Biotech Hunter | Biotech Hunter